Matching Adjusted Indirect Comparisons of Personalized Prophylaxis with Simoctocog Alfa Versus Efmoroctocog Alfa, Damoctocog Alfa Pegol and Rurioctocog Alfa Pegol in Patients with Hemophilia a

被引：0
|
作者：
Kessler, Craig M. [1 ]
Tiede, Andreas [2 ]
机构：
[1] Georgetown Univ, Sch Med, Washington, DC USA
[2] Hannover Med Sch, Clin Haematol Haemostaseol Oncol & Stem Cell Tran, Hannover, Germany
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-162205
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2755 / 2756
页数：2
相关论文
共 50 条
  • [21] MATCHING ADJUSTED INDIRECT COMPARISONS BETWEEN PERSONALISED PROPHYLAXIS WITH SIMOCTOCOG ALFA VERSUS STANDARD PROPHYLAXIS WITH EMICIZUMAB IN ADULTS WITH SEVERE HAEMOPHILIA A
    Kessler, C.
    Corrales-Medina, F.
    Tarantino, M.
    HAEMOPHILIA, 2023, 29 : 33 - 34
  • [22] COST-MINIMIZATION ANALYSIS OF DAMOCTOCOG ALFA PEGOL IN SEVERE HEMOPHILIA A IN GREECE.
    Vellopoulou, K.
    Georgilis, A.
    Byrne, A.
    Gray, E.
    De Meyer, N.
    Kourlaba, G.
    VALUE IN HEALTH, 2019, 22 : S848 - S848
  • [23] Personalised prophylaxis with simoctocog alfa versus standard emicizumab prophylaxis in haemophilia A, a matching-adjusted indirect comparison
    Kessler, C. M.
    Corrales-Medina, F. F.
    MannuccioMannucci, P.
    Astermark, J.
    Tarantino, M. D.
    HAEMOPHILIA, 2024, 30 : 55 - 55
  • [24] INDIRECT COMPARISON OF PROPHYLAXIS EFFICACY BETWEEN SIMOCTOCOG ALFA AND EFANESOCTOCOG ALFA IN SEVERE HEMOPHILIA A AND THEIR COST IN THE UNITED STATES
    Kessler, Craig M.
    Corrales-Medina, Fernando F.
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 100 : 62 - 63
  • [25] Pharmacokinetics of recombinant factor VIII in adults with severe hemophilia A: fixed-sequence single-dose study of octocog alfa, rurioctocog alfa pegol, and efanesoctocog alfa
    Lissitchkov, Toshko
    Willemze, Annemieke
    Jan, Christelle
    Zilberstein, Moshe
    Katragadda, Suresh
    RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS, 2023, 7 (04)
  • [26] Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study
    Klamroth, Robert
    Windyga, Jerzy
    Radulescu, Vlad
    Collins, Peter W.
    Stasyshyn, Oleksandra
    Ibrahim, Hishamshah Mohd
    Engl, Werner
    Tangada, Srilatha D.
    Savage, William
    Ewenstein, Bruce
    BLOOD, 2021, 137 (13) : 1818 - 1827
  • [27] EU Approval for Esperoct® (Turoctocog alfa pegol) for Hemophilia A
    不详
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2019, 46 (04) : 299 - 299
  • [28] CLINICAL OUTCOMES IN PATIENTS WITH HAEMOPHILIA A AFTER SWITCHING TO RURIOCTOCOG ALFA PEGOL PROPHYLAXIS IN THE ATHN 2 STUDY
    Journeycake, J.
    Caicedo, J.
    Cheng, D.
    Denne, M.
    Guelcher, C.
    Lattimore, S.
    Mokdad, A.
    Ragni, M.
    Recht, M.
    Sidonio, R., Jr.
    Takemoto, C.
    Tarantino, M. D.
    Watson, C. W. Crystal
    Neufeld, E.
    HAEMOPHILIA, 2021, 27 : 55 - 56
  • [29] Safety and Efficacy of Damoctocog Alfa Pegol Prophylaxis in Patients with Severe Hemophilia A: Interim Results of a Post-Marketing, Interventional Study
    Andre Holme, Pal
    Hvitfeldt Poulsen, Lone
    Tueckmantel, Claudia
    Alvarez Roman, Maria Teresa
    De Cristofaro, Raimondo
    BLOOD, 2021, 138
  • [30] DESIGN OF A POST-AUTHORIZATION LONG-TERM SAFETY STUDY FOR RURIOCTOCOG ALFA PEGOL IN PATIENTS WITH HEMOPHILIA A
    Zhang, J.
    Botha, J.
    Allen, G.
    HAEMOPHILIA, 2021, 27 : 62 - 62
12345